ACRO Biomedical Co., Ltd.(TW:6748)
NT$169.50+1.00 (+0.59%)
TW:6748
ACRO Biomedical Co., Ltd. financials statements
NT$169.50
At close:+1.00 (+0.59%)
ACRO Biomedical Co., Ltd. (6748) Ratios
ACRO Biomedical Co., Ltd. Ratios
TW:6748's free cash flow for Q2 2026 was NT$-59.09M. For the 2026 fiscal year, TW:6748's free cash flow was decreased by NT$-5.31M and operating cash flow was NT$-53.78M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 51.12 | 28.68 | 41.04 | 27.68 | 9.01 |
| Quick Ratio | 50.47 | 28.10 | 40.40 | 26.69 | 7.72 |
| Cash Ratio | 39.16 | 10.39 | 36.74 | 22.23 | 2.85 |
| Solvency Ratio | -2.35 | -1.67 | -0.99 | -2.59 | -1.94 |
| Operating Cash Flow Ratio | -2.49 | -2.35 | -3.26 | -3.56 | -4.22 |
| Short-Term Operating Cash Flow Coverage | -22.68 | 0.00 | -86.19 | -49.84 | -1086.98 |
| Net Current Asset Value | NT$ 977.79M | NT$ 500.33M | NT$ 577.15M | NT$ 330.92M | NT$ 80.91M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.03 | 0.03 | 0.09 |
| Debt-to-Equity Ratio | 0.01 | 0.03 | 0.03 | 0.03 | 0.10 |
| Debt-to-Capital Ratio | 0.01 | 0.02 | 0.03 | 0.03 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.03 | 1.05 | 1.04 | 1.05 | 1.16 |
| Debt Service Coverage Ratio | -31.73 | -168.97 | -36.72 | -51.26 | -311.98 |
| Interest Coverage Ratio | -411.68 | -232.52 | -185.76 | -627.75 | -608.58 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.18 | 0.26 | 0.42 | 0.25 | 0.38 |
| Net Debt to EBITDA | 10.04 | 3.64 | 17.31 | 5.24 | 0.46 |
| Profitability Margins | |||||
| Gross Profit Margin | 31.81% | 59.21% | 76.60% | 48.59% | 66.62% |
| EBIT Margin | -241.06% | -139.68% | -80.60% | -219.97% | -232.21% |
| EBITDA Margin | -197.84% | -109.21% | -59.10% | -186.63% | -188.67% |
| Operating Profit Margin | -241.06% | -150.35% | -95.31% | -227.17% | -245.35% |
| Pretax Profit Margin | -216.06% | -140.33% | -81.11% | -220.33% | -232.61% |
| Net Profit Margin | -216.06% | -140.37% | -81.11% | -220.33% | -232.61% |
| Continuous Operations Profit Margin | -216.06% | -140.37% | -81.11% | -220.33% | -232.61% |
| Net Income Per EBT | 100.00% | 100.03% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 89.63% | 93.34% | 85.10% | 96.99% | 94.81% |
| Return on Assets (ROA) | -7.30% | -9.47% | -5.78% | -15.28% | -33.56% |
| Return on Equity (ROE) | -7.48% | -9.91% | -6.04% | -16.08% | -39.05% |
| Return on Capital Employed (ROCE) | -8.29% | -10.44% | -6.93% | -16.27% | -38.27% |
| Return on Invested Capital (ROIC) | -8.27% | -10.36% | -6.88% | -16.08% | -37.35% |
| Return on Tangible Assets | -7.34% | -9.57% | -5.85% | -15.59% | -35.43% |
| Earnings Yield | -2.05% | -3.97% | -2.02% | -6.43% | -5.40% |
| Efficiency Ratios | |||||
| Receivables Turnover | 11.14 | 4.64 | 6.21 | 2.64 | 3.46 |
| Payables Turnover | 25.30 | 24.16 | 30.79 | 47.51 | 117.52 |
| Inventory Turnover | 2.05 | 1.69 | 1.26 | 1.14 | 0.50 |
| Fixed Asset Turnover | 0.58 | 0.65 | 1.03 | 1.21 | 0.82 |
| Asset Turnover | 0.03 | 0.07 | 0.07 | 0.07 | 0.14 |
| Working Capital Turnover Ratio | 0.05 | 0.08 | 0.11 | 0.13 | 0.19 |
| Cash Conversion Cycle | 196.07 | 280.08 | 337.55 | 452.01 | 835.05 |
| Days of Sales Outstanding | 32.76 | 78.71 | 58.79 | 138.27 | 105.45 |
| Days of Inventory Outstanding | 177.74 | 216.48 | 290.61 | 321.42 | 732.71 |
| Days of Payables Outstanding | 14.43 | 15.11 | 11.85 | 7.68 | 3.11 |
| Operating Cycle | 210.49 | 295.19 | 349.40 | 459.69 | 838.15 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.80 | -0.71 | -0.92 | -0.95 | -1.35 |
| Free Cash Flow Per Share | -1.03 | -1.21 | -1.35 | -1.05 | -1.44 |
| Dividend Paid and CapEx Coverage Ratio | -3.51 | -1.42 | -2.15 | -10.17 | -14.48 |
| Capital Expenditure Coverage Ratio | -3.51 | -1.42 | -2.15 | -10.17 | -14.48 |
| Operating Cash Flow Coverage Ratio | -4.63 | -2.74 | -2.23 | -3.82 | -3.58 |
| Operating Cash Flow to Sales Ratio | -1.28 | -0.98 | -0.95 | -1.63 | -2.19 |
| Free Cash Flow Yield | -1.56% | -4.73% | -3.45% | -5.23% | -5.43% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -48.89 | -25.30 | -49.43 | -15.50 | -18.53 |
| Price-to-Sales (P/S) Ratio | 105.63 | 35.36 | 40.09 | 34.29 | 43.11 |
| Price-to-Book (P/B) Ratio | 3.66 | 2.50 | 2.98 | 2.50 | 7.24 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -64.18 | -21.13 | -28.94 | -19.11 | -18.40 |
| Price-to-Operating Cash Flow Ratio | -82.45 | -36.06 | -42.41 | -20.99 | -19.67 |
| Price-to-Earnings Growth (PEG) Ratio | -1.45 | -0.91 | 1.28 | 1.58 | 1.39 |
| Enterprise Value Multiple | -43.35 | -28.74 | -50.52 | -13.14 | -22.39 |
| Enterprise Value | 3.28B | 1.39B | 1.52B | 677.56M | 922.04M |
| EV to EBITDA | -43.35 | -28.74 | -50.52 | -13.14 | -22.39 |
| EV to Sales | 85.76 | 31.38 | 29.86 | 24.52 | 42.24 |
| EV to Free Cash Flow | -52.11 | -18.76 | -21.56 | -13.66 | -18.03 |
| EV to Operating Cash Flow | -66.94 | -32.01 | -31.59 | -15.01 | -19.28 |
| Tangible Book Value Per Share | 17.93 | 10.13 | 12.92 | 7.82 | 3.44 |
| Shareholders’ Equity Per Share | 18.04 | 10.23 | 13.09 | 7.99 | 3.66 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.62 | 0.72 | 0.97 | 0.58 | 0.61 |
| Net Income Per Share | -1.35 | -1.01 | -0.79 | -1.29 | -1.43 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.90 | 1.00 | 1.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.81 | 0.58 | 0.56 | 1.01 | 1.19 |
| SG&A to Revenue | 2.11 | 1.51 | 1.09 | 1.75 | 1.93 |
| Stock-Based Compensation to Revenue | 0.32 | 0.03 | 0.00 | 0.03 | 0.06 |
| Income Quality | 0.59 | 0.70 | 1.17 | 0.74 | 0.94 |
Currency in TWD
